Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Dr. Daniel (Danny) Song is a Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer. Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy. Dr. Song's research interests include the development and refinement of new imaging methods to improve radiation targeting, as well as innovative means of reducing potential side effects of radiation treatment. His research is supported by federal and private research funding programs including two R01 awards from the National Cancer Institute, Department of Defense Prostate Cancer Clinical Trial Award, the American Cancer Society, and the Hopkins-BMS Immuno-Oncology Consortium. He is a reviewer and examiner for the American Board of Radiology, which administers the national board certification examination for radiation oncologists. He has served on the editorial boards of the International Journal of Radiation Oncology, Biology, Physics and The Prostate, and on the scientific review committees for the American Society for Radiation Oncology (ASTRO), American Brachytherapy Society, and the Dept of Defense Prostate Cancer Research Program. He currently serves on the Scientific Planning Committee for the American Brachytherapy Society annual meeting. He has co-authored consensus guidelines on stereotactic body radiation therapy (TG-101) and image-guided robotic brachytherapy (TG-192) produced by the American Association of Physics in Medicine. Dr. Song sees patients at the Johns Hopkins Hospital (downtown Baltimore) as well as Greenspring Station (Timonium) practices. Make A Gift. Dr. Song is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Prostatectomy, and Endoscopy.

Dr. John Migaly is a distinguished colorectal surgeon and Chief of the Division of Colorectal Surgery/Ravitch Division at Johns Hopkins Medicine. He specializes in the treatment of colorectal cancer, inflammatory bowel disease, and other benign and complex colorectal conditions. Dr. Migaly is committed to providing advanced, patient-centered care, often using minimally invasive techniques including laparoscopic and robotic surgery, to help reduce recovery time and improve outcomes. Dr. Migaly comes to Johns Hopkins Medicine from the Duke University School of Medicine, serving from 2008-2024 on the surgery faculty treating patients primarily through the Duke Cancer Institute. He was elevated to Program Director of the General Surgery Residency in 2012, and subsequently served as Vice Chair of Education until 2024. His work was critical to the success of the undergraduate, graduate, and continuing medical education missions at Duke Surgery. Dr. Migaly earned his B.A. in Biochemistry from New York University and his medical degree from the New York University School of Medicine. He completed surgical residency and a research fellowship at Temple University Health Sciences Center, and colorectal surgery fellowship at Cleveland Clinic Florida. Dr. Migaly’s career has been marked not only by a complex and high-volume clinical colon and rectal surgery practice, but also a commitment to research and education, supported by greater than 200 publications, book chapters, and presentations. His research is centered around improving practice patterns and outcomes in colorectal cancer care and recovery. His leadership and dedication to advancing the field of colorectal surgery is evident through his service on committees that shape how colorectal care is delivered nationally, via his past and present service on the Program Committee, the Clinical Practice Guidelines Committee and the Diversity and Inclusion Committee of the American Society of Colon and Rectal Surgeons. Videos John Migaly, M.D.Chief of Colorectal Surgery"". Dr. Migaly is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Familial Colorectal Cancer, Gastroesophageal Junction Cancer, Anal Cancer, Colostomy, and Ileostomy.

Ilene S. Browner, M.D. specializes in geriatric oncology. Dr. Browner is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Endoscopy.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Liver Embolization.

Jessica Engle, D.O., is a rehabilitation physician specializing in cancer rehabilitation, with clinic locations in the Baltimore metropolitan area and Washington. Dr. Engle uses a multidisciplinary approach to treat the whole patient throughout the cancer care continuum. Her focus is on addressing cancer and impairments related to cancer treatment. She aims to improve quality of life, and maintain and improve function whenever possible. Dr. Engle is an assistant professor of physical medicine and rehabilitation at the Johns Hopkins University School of Medicine. She completed a fellowship in cancer rehabilitation at the University of Texas MD Anderson Cancer Center after a physical medicine and rehabilitation residency at Stony Brook University. Videos Dr. Jessica Engle. Dr. Engle is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Lymphedema, and Primary Intestinal Lymphangiectasia.

Sunil H. Patel, M.D., M.A., is an Assistant Professor of Urology and Oncology at the School of Medicine at Johns Hopkins. He serves as and the Director of the Urologic Oncology Fellowship. He also serves as Director of the Testicular Cancer program. He treats all urologic malignancies, including adrenal cancer, kidney cancer, urothelial cancer, bladder cancer, prostate cancer, testes cancer, and penile cancers. Additionally, he has advanced training in complex robotic and open surgical cases. His clinical and research focus is in Urologic Oncology, with areas of focus in bladder cancer, testes cancer, and kidney cancer. Dr. Patel completed his undergraduate studies at California Polytechnic State University, San Luis Obispo where he studied Biological Sciences. He completed his Masters at Boston University, completing his thesis on microfluidics, afterwards completing his medical degree at Boston University. He completed his general surgery internship and urology residency at University of California, San Diego. He continued his training through a Society of Urologic Oncology Fellowship in urologic oncology at the Johns Hopkins Hospital. He joined Johns Hopkins in June 2020 with interests in environmental factors contributing to oncogenesis in urological cancers, especially bladder cancer. He is dedicated to international health and works closely with international volunteers in urology and has done several mission trips and guest lectures. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Dr. Atif Zaheer is a Professor of Radiology and Radiological science at Johns Hopkins University School of Medicine, as well as the director of the Cross-Sectional Body Imaging Fellowship program. Dr. Zaheer practices at the Johns Hopkins Hospital in Baltimore, MD. Dr. Zaheer earned his medical degree from the Aga Khan University. He completed a residency in diagnostic radiology at Beth Israel Deaconess Medical Center/Harvard Medical School, followed by a fellowship in abdominal imaging and interventional radiology at Brigham and Women’s Hospital/Harvard Medical School. Dr. Zaheer is also the medical director of the e-Radiology learning program at Johns Hopkins, which provides radiology residents and practicing radiologists around the world with a lecture series designed to address core knowledge of normal anatomy, pathology and background physics required for successful practice of the field. Dr. Zaheer is clinically active in cross-sectional imaging of the body using CT, MRI and Ultrasound and is also involved in multidisciplinary conferences for pancreas, liver and rectal cancer imaging. His research interests include imaging of tumors and inflammatory disorders of the pancreas and is considered a leader in pancreatic imaging. He is the associate editor of the journal Abdominal Radiology and actively participates in clinical trials, publishes scientific articles, authors books on pancreatic and gastrointestinal imaging, and gives talks at national and international conferences. Dr. Zaheer is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Pancreatic Ductal Adenocarcinoma, Pancreas Divisum, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Satomi Kawamoto is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. She specializes in computed tomography (CT), ultrasound, and image-guided biopsy. Dr. Kawamoto received her M.D. from Gunma University in Gunma, Japan, and subsequently completed two residencies, one in internal medicine at St. Luke’s International Hospital in Tokyo, and a second in diagnostic radiology at Johns Hopkins. She received a postdoctoral fellowship in cross-sectional imaging at Johns Hopkins, and then joined the Johns Hopkins faculty. Dr. Kawamoto’s research focuses on body CT and biopsy, particularly imaging of the genitourinary and gastrointestinal systems. Dr. Kawamoto is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Neuroendocrine Tumor, Muscle Invasive Bladder Cancer, Cavernous Lymphangioma, Hepato-Pancreato-Biliary Surgery, and Pancreaticoduodenectomy.

"Dr. Katarzyna J. Macura is a professor in the Johns Hopkins Medicine department of radiology and radiological science, a professor of oncology and urology at the Johns Hopkins University School of Medicine, and a member of the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins Precision Medicine Center of Excellence for Prostate Cancer. She is a radiologist consultant for the Prostate Cancer Multidisciplinary Clinic at The Johns Hopkins Hospital in Baltimore, MD. Dr. Macura established a clinical and research prostate imaging program with a focus on magnetic resonance imaging (MRI). Dr. Macura has expertise in cross-sectional body imaging, MRI and prostate cancer, and image-guided biopsies. Dr. Macura earned her medical degree from the Medical University of Lodz in Poland. She completed a residency in diagnostic radiology at the Medical College of Georgia and a fellowship in cross-sectional body imaging at Johns Hopkins University. Prior to arrival at Hopkins in 2000, Dr. Macura completed post-doctoral research in Artificial Intelligence at the University of Georgia in Athens, GA. With a PhD degree in Medical Informatics, she had pioneered early applications of Artificial Intelligence for medical decision support, a domain that is now rapidly expanding owing to the advancement of computer technologies and recent recognition that decision support augments appropriate utilization of medical technologies, provides second opinion systems for improved diagnostics and management, and allows optimization of medical care delivery with the assessment of quality and safety. Dr. Macura is a certified knowledge engineer. Dr. Macura is a member of several national and international radiology organizations. She served as president of the Maryland Radiological Society, the Maryland Chapter of the American College of Radiology (ACR), between 2013 and 2015, as well as president of the American Association for Women in Radiology (AAWR) in 2005. She was a Chancellor on the ACR Board of Chancellors, serving as the Inaugural Chair of the ACR Commission for Women and Diversity, between 2013 and 2019. She served as Vice-President of the ACR 2019-2020. She was named the Outstanding Teacher of the Year by Hopkins Radiology Residents in 2005 and 2021, and received the Resident Mentoring Awards in 2018 and 2024. Dr. Macura was also named the Honored Educator by the Radiological Society of North America in 2012 and 2014. In 2016, she received the ""Diamond"" Jim Brady Urology Residents teaching award and the AAWR Marie Sklodowska-Curie award. In 2022, she received the Gold Medal from the American College of Radiology. Dr. Macura is a Fellow of the American College of Radiology (FACR), the Society for Advanced Body Imaging (FSABI), and the American Association for Women in Radiology (FAAWR).". Dr. Macura is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Muscle Invasive Bladder Cancer, Fibrolamellar Carcinoma, Renal Cell Carcinoma (RCC), Prostatectomy, and Penectomy.

Dr. Linda Chi Hang Chu is an Associate Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Her clinical expertise includes body CT, MRI and US. Her research interests include abdominal imaging, cancer imaging, radiomics, and artificial intelligence. Dr. Chu graduated from the University of Toronto in 2003 and was awarded the Governor General's Silver Medal, the highest academic achievement from the undergraduate program. She earned her medical degree as a member of AOA and phi beta kappa from Johns Hopkins University in Baltimore, MD in 2007. She completed her Diagnostic Radiology residency and body MRI fellowship at Johns Hopkins Hospital. Dr. Chu joined the Johns Hopkins faculty in 2013. Dr. Chu is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, ALK-Positive Non-Small Cell Lung Cancer, Muscle Invasive Bladder Cancer, Pancreaticoduodenectomy, and Gallbladder Removal.

Peter Filderman is an Urologist in Baltimore, Maryland. Dr. Filderman is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Enlarged Prostate (BPH), UPJ Obstruction, Urinary Tract Infection in Children, Ureteroscopy, and Bladder Reconstruction.

Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Dr. Johnson is a genitourinary medical oncologist who specializes in treating patients with bladder cancer and upper tract urothelial carcinoma. He is a member of the Greenberg Bladder Cancer Institute. He obtained his M.D. and Ph.D. degrees from the Medical College of Georgia, where he completed his residency in Internal Medicine. He then completed his medical oncology fellowship and did additional postdoctoral research at Johns Hopkins before joining the faculty. He has an active laboratory which focuses on optimizing bladder cancer preclinical models, studying mechanisms of bladder cancer progression, elucidating biomarkers that correlate with bladder cancer survival and response to treatment, and testing immunotherapies in bladder cancer preclinical models. His research has been funded by an ASCO Young Investigator Award, an AACR-BMS Fellowship for Young Investigators in Translational Immuno-oncology, a Harry J. Lloyd Charitable Trust Career Development Award, a Bladder Cancer Advocacy Network Young Investigator Award, and a Department of Defense Career Development Award. Dr. Johnson is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bladder Cancer, and Urothelial Cancer.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Dr. Daniel Ford is a professor of medicine at the Johns Hopkins University School of Medicine. He holds joint appointments in psychiatry and behavioral sciences and, at the Johns Hopkins Bloomberg School of Public Health, in health policy and management and in epidemiology. Dr. Ford serves as the director of the Institute for Clinical and Translational Research and the senior associate dean for clinical and translational research at the Johns Hopkins School of Medicine. Widely regarded as a pioneer in research associated with the interrelationships between mental disorders and chronic medical conditions, Dr. Ford gained international acclaim for clinical studies documenting depression as an independent risk factor for coronary heart disease and for research describing the long-term health risks related to sleep disturbances. He was chosen by the Robert Wood Johnson Foundation to direct the evaluation of its $12 million Depression in Primary Care Initiative. He also has been the principal researcher on a large training grant to develop researchers in general internal medicine. A leader in using the Internet for clinical research, Dr. Ford worked closely with Johns Hopkins personnel who developed e-IRB, an electronic process for submitting research proposals to the school of medicine’s Institutional Review Board, which oversees requests to launch clinical studies. His research interests include ways to improve the treatment of chronic diseases through information technology. He also advocates treating human research subjects as partners, ensuring that they receive sufficient thanks for their commitment and willingness to contribute to scientific progress. Dr. Ford received his M.D. from the State University of New York at Buffalo in 1982. He arrived at Hopkins that year as a medical resident and, except for a brief period as a National Institutes of Health fellow, has been on the Johns Hopkins faculty ever since. He received his master’s degree in public health from the Bloomberg School in 1986. He has published more than 120 research papers and book chapters, and was associate editor of the Journal of General Internal Medicine and a member of the editorial board of General Hospital Psychiatry. Dr. Ford is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Agranulocytosis, Glucocorticoid-Remediable Aldosteronism, and Hypertension.

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.